Steven yule

Biography

 Dr. Steven Murray Yule has served as Clinical Development Officer at BERGENBIO ASA since November 1, 2016. Dr. Murray Yule joined BerGenBio in 2011 as a consultant. He began his career in the pharmaceutical industry in 1998 after completing his medical training in oncology at Addenbrookes Hospital, Cambridge. Whilst working in the United Kingdom’s National Health Service, Murray supervised multiple early phase clinical studies of novel anticancer products and completed a PhD in experimental pharmacology. In the last ten years, whilst working in several top-ten pharmaceutical companies, he has planned and executed global development strategies for several anticancer drugs, which has led to licensing approvals for novel tubulin binders in solid tumors and epigenetic therapies in acute leukemia. Dr. Murray Yule also provides clinical development consulting to Incanthera Limited, Bicycle Therapeutics and the British Therapeutics Group. He serves at Pentlands Oncology Consulting Ltd (board member) and was previously employed at Pentlands Clinical Resourcing Limited (board member) and Astex Therapeutics Limited (medical director).

Research Interest

 Pharmaceutical